The study used an at-home device that was then self administered once daily 6x/week for 12 weeks
the device parameters are: 810nm transcranial PBM for 20min, power density 150mw/cm2, Pulse 40hz, duty cycle 42%, beam spot 3cm, Joules 300/session. Same protocol used as the Cognitolite trial (Nizmutdinov, 2021) with sham control showing the operating lights but no PBM delivery. This study only delivered light to default mode network (DMN), including frontal, parietal, posterior precuneus, and posterior cingulate. Results were somewhat positive but limited by virtue of the lower wavelength and distribution of the stimulation compared to the Cognitolite that was fully transcranial and intraocular. This led to more robust improvements in memory, mood and motor functioning in that mild to moderate AD cohort.
0 Comments
Your comment will be posted after it is approved.
Leave a Reply. |
QMF NewsOur team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general. Archives
October 2024
Categories
All
|